Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)
- Previous Close
12.01 - Open
12.00 - Bid --
- Ask --
- Day's Range
12.01 - 12.01 - 52 Week Range
8.88 - 15.52 - Volume
15 - Avg. Volume
1,686 - Market Cap (intraday)
144 - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
80.07 - EPS (TTM)
0.15 - Earnings Date May 15, 2024 - May 18, 2024
- Forward Dividend & Yield 0.17 (1.43%)
- Ex-Dividend Date Sep 28, 2023
- 1y Target Est
--
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. Further it provides Clarith, a macrolide antibiotic; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products, as well as engages in real estate leasing, management, possession, and operation. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is based in Tokyo, Japan.
www.taisho-holdings.co.jp8,784
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TAIPY
Performance Overview: TAIPY
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TAIPY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TAIPY
Valuation Measures
Market Cap
144.00
Enterprise Value
-1.71B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
2.63%
Return on Assets (ttm)
1.21%
Return on Equity (ttm)
1.30%
Revenue (ttm)
320.38B
Net Income Avi to Common (ttm)
8.42B
Diluted EPS (ttm)
0.15
Balance Sheet and Cash Flow
Total Cash (mrq)
266.37B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: TAIPY
Company Insights: TAIPY
TAIPY does not have Company Insights